Which is your choice? Neoadjuvant doxorubicin hydrochloride and doxetaxel (AD) versus doxorubicin hydrochloride, cyclophosphamide, and paclitaxel (AC-T) in locally advanced breast cancer

被引：0
|
作者：
Kang, Seok Yun
Choi, Jin-Hyuk
Kim, Ku Sang
机构：
[1] Ajou Univ, Sch Med, Suwon 441749, South Korea
[2] Ajou Univ Hosp, Suwon, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11559
引用
收藏
页数：1
相关论文
共 50 条
  • [1] WHICH IS YOUR CHOICE? NEOADJUVANT DOXORUBICIN AND DOXETAXEL (AD) VERSUS DOXORUBICIN, CYCLOPHOSPHAMIDE AND PACLITAXEL (ACT) IN LOCALLY ADVANCED BREAST CANCER
    Kim, K. S.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 15 - 15
  • [2] WHICH IS YOUR CHOICE? NEOADJUVANT ADRIAMYCIN AND DOXETAXEL (AD) VERSUS ADRIAMYCIN, CYCLOPHOSPHAMIDE AND PACLITAXEL (AC-T) IN LOCALLY ADVANCED BREAST CANCER
    Kang, S. Y.
    Choi, J. -H.
    Lee, H. W.
    Ahn, M.
    Kim, K. S.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 127 - 127
  • [3] WHICH IS YOUR CHOICE?; NEOADJUVANT ADRIAMYCIN AND DOXETAXEL (AD) VERSUS ADRIAMYCIN, CYCLOPHOSPHAMIDE AND PACLITAXEL(AC-T) IN LOCALLY ADVANCED BREAST CANCER
    Kang, S. Y.
    Kim, K. S.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 135 - 135
  • [4] Breast conserving surgery after neoadjuvant chemotherapy paclitaxel plus doxorubicin vs fluorouracil plus doxorubicin plus cyclophosphamide in locally advanced breast cancer.
    Semlglazov, VF
    Bojok, AA
    Arsumanov, AS
    Ivanova, OA
    Ivanov, VG
    Semlglazov, VV
    Pozharissky, KM
    Topuzov, AE
    Nurgaziev, KS
    Paltuev, KS
    Petrov, RM
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S52 - S52
  • [5] Analysis of response to neoadjuvant chemotherapy (NCT) with doxorubicin plus cyclophosphamide followed by paclitaxel (AC- T) in triple negative locally advanced breast cancer (LABC) in Brazil
    Nunes, J. S.
    Tsunoda, A. T.
    Viana, L. S.
    Souza, F. H.
    Castro, N.
    Hohmann, J.
    Serrano, S. V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Doxorubicin and cyclophosphamide followed by weekly docetaxel (AC-T) as neoadjuvant chemotherapy in operable breast cancer patients:: GEICAM 2002-03 Study
    Estévez, LG
    Adrover, E
    Barnadas, A
    Cuevas, JM
    Seguí, MA
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S229 - S229
  • [7] A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer
    Vujaskovic, Zeljko
    Kim, Dong W.
    Jones, Ellen
    Lan, Lan
    Mccall, Linda
    Dewhirst, Mark W.
    Craciunescu, Oana
    Stauffer, Paul
    Liotcheva, Vlayka
    Betof, Allison
    Blackwell, Kimberly
    [J]. INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2010, 26 (05) : 514 - 521
  • [8] A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel and hyperthermia in locally advanced breast cancer
    Kim, D. W.
    Blackwell, K.
    Vujaskovic, Z.
    Craciunescu, O.
    Stauffer, P.
    Liotcheva, V.
    Jones, E.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S183 - S184
  • [9] Comparison of Efficiency and Side Effect of Adriamycin and Doxetaxel and Adriamycin, Cyclophosphamide and Paclitaxel in Patients with Locally Advanced Breast Cancer Receiving Neoadjuvant Chemotherapy
    Hong, W.
    Kim, K.
    Jung, Y.
    Kim, J.
    Kang, S.
    Chun, J.
    Chun, M.
    Yim, H.
    Kang, D.
    Kim, T.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : S172 - S173
  • [10] Neoadyuvant therapy with dose-dense (DD) docetaxel (T) and doxorubicin/cyclophosphamide (AC) in locally advanced breast cancer (LABC)
    Mata, J. G.
    Antolin, S.
    Mel, J. R.
    Ramos, M.
    Garcia-Palomo, A.
    Almanza, M. C.
    De Paz, L.
    Calvo Martinez, L.
    Alvarez, E.
    Gonzalez-Quintas, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345